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Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a recently recognized provisional entity in the 2017 revision
of the World Health Organization classification of lymphoid neoplasms. Although the majority of the cases described in the
literature demonstrate an effusion confined to the capsule of the breast implant, this rare pathology can also invade the capsule
and adjacent tissues and/or involve lymph nodes. We hereby report two new cases of BIA-ALCL in a 58-year-old and a 47-year-
old Caucasian female who received a silicone breast implant. The first patient showed a sudden and rapid right breast volume
increase 6 years after the implantation surgery. As for the second patient, a left breast volume increase was observed also suddenly
and quickly 11 years after surgery. In both cases, an uncompressed mammography was performed allowing a new approach to
highlight periprosthetic fluid reaction. Pathologic examination of the fluid collection revealed atypical cells positive for CD30
and CD45 and negative for ALK and CK7. This allowed pathologists to diagnose a breast implant-associated anaplastic large cell
lymphoma. Patients were treated with bilateral capsulectomy with no additional local or systemic therapy. The development of
breast augmentation may come with an increase in the frequency of this pathology. Radiologists and senologists must therefore
be careful when women with breast implants show an increase of breast volume and all cases of BIA-ALCL must be recorded and
reported.
1. Introduction
Malignant Lymphomas of the breast are rare and account
for less than 0.5% of all malignant breast tumors [1, 2].
The most common types of breast lymphomas are B-cell
lymphomas with only rare cases showing T-cell phenotype [3,
4]. Anaplastic lymphoma kinase (ALK) negative anaplastic
large T-cell lymphoma (ALCL) is a rare form of Non-
Hodgkin’s lymphoma [5]. Breast implant-associated ALK-
negative ALCL (BIA-ALCL ALK negative) has been reported
for the first time in 1997 by Keech and Creech [6] and 14 years
passed before it was recognized as a distinct clinicopathologic
entity [5]. In 2017, BIA-ALCL was identified as a provisional
entity in the revisedWHO 2017 classification [7]. In February
2019, the US Food and Drug Administration (FDA) analyzed
660 medical devices reports (MDRs) of BIA-ALCL and
concluded that 457 MDRs meet the pathologic criteria of
BIA-ALCL [8]. Some authors described two subtypes of BIA-
ALCL, the in situ BIA-ALCL consisting of an anaplastic
proliferation with “hallmark” cells confined to the capsule
in association with seroma and the infiltrative BIA-ALCL
where cells infiltrate the capsule and/or adjacent tissues and
is associated with a tumor mass [9]. Today it seems more
appropriate to consider the clinical and pathologic staging
of BIA-ALCL following the TNM staging system defined by
Clements et al. [10]. In this tumor staging system, T1 means
that the lymphoma cells are confined to the luminal surface,
T2 indicates an early capsule invasion, T3 when tumors cells
invade deep into the capsule but not beyond and T4 implies
the presence of a mass and tumor cells out of the capsule [10].
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Figure 1: Mediolateral oblique view of the right breast shows a rim of density surrounding the silicone implant (white arrow).
The treatment of patients with BIA-ALCL will be adjusted
according to the stage of the disease. However, the complete
surgery involving a total capsulectomy and the breast implant
removal is the optimal treatment for most patients. An
incomplete resection, an associated mass, or an involvement
of lymph node will require an adjuvant treatment such as
chemotherapy or radiation therapy [10–13]. There is no role
for a radical mastectomy and sentinel node biopsy, and full
axillary dissection is reserved only for multinode metastasis.
The prognosis of the disease mostly depends on the extent
of the disease at the time of diagnosis. Compared with many
other subtypes systemic T-cell lymphoma, the prognosis of
BIA-ALCL in early stage is excellent [11, 12].
In this study we report two clinical cases of BIA-ALCL
found at the same institution. This case report contributes to
a better understanding of this pathology and may be helpful
in determining the best treatment for these patients.
2. Cases Presentation
2.1. Case 1. A 58-year-old woman came to our Center of
Senology with an increase in volume of her right breast
without sign of an infection. She is the mother of four
children and under IUDMirena and estrogel treatments. Her
breast surgery history is the following: in 2003, excisional
biopsy of a cluster of superior right-sided calcifications
corresponding to benign calcifications on focus of fibrocystic
mastopathy; in 2004, breast augmentation with retropectoral
silicone implants and mastopexy; in 2011, replacement of
implants following intracapsular rupture of the left one. The
reference of her implants is the following: Allergan Inspira
TSLP with volume of 300cc and textured surface. In her
hereditary history, her maternal grandmother was diagnosed
with breast cancer. The clinical examination revealed that
her breasts are clearly dissymmetrical. The right breast being
much larger and bulging than the left one, without suspicious
mass detected. There is no skin retraction, no erythema, and
no palpable lymphadenopathy. When performing mammog-
raphy on a patient with breast implants, the guidelines specify
to use Eklund’s technique [14]. This technique comes with a
limitationwith the breast implant not visible on the photogra-
phy. Consequently, we always perform an X-ray of the entire
breast without compression before applying themethod.This
allows us to check the integrity of the prosthesis, to locate
it and to estimate the proportion of mammary glands. Our
center is equipped with a senographe Essential Full-Field
Digital System from General Electric (GE) medical system
company. On the mammography, the mediolateral oblique
(MLO) viewwithout compression demonstrates that the right
prosthesis is deformed on its anterior surface (Figure 1). In
addition, there is a predominantly periprosthetic effusion
on the anterior surface, which explains this deformation of
the prosthesis. The effusion seems located in the prosthetic
capsule. In Eklund incidence, no lesion has been observed.
We performed a bilateral ultrasound with Canon Aplio i600
from Canon medical system company. This exam does not
show any tumoral lesion or cyst. But it confirms the existence
of a significant right periprosthetic fluid reaction. To obtain a
diagnosis, a partial evacuation by fine needle aspiration was
performed and 100cl of yellowish liquid was removed. The
bacteriologic analysis of a part of this sample demonstrates no
sign of infection.Thepathologic evaluation of the second part
of this sample firstly reveals the presence of atypical cells (Fig-
ure 2(a)). Immunohistochemical analysis then demonstrated
a moderate and diffused expression of CD30 (Figure 2(b)).
Moreover CD45 and Vimentins are expressed while ALK and
CK7 are not. This sample was submitted for a blind analysis
to four independent anatomopathologists who all came to
the conclusion of a breast implant-associated anaplastic large
cell lymphoma. The effusion is confined between the capsule
and the prosthesis without extension beyond the capsule
of the implant and no mass or lymph node is detected.
Thus, the BIA-ALCL-specific TNM staging system designed
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Figure 2: Case 1, representative section of the cell block preparation from effusion fluid. (a) A cluster of lymphoma cells is observed
(hematoxylin and eosin); (b) CD30 expression by the neoplastic cells of BIA-ALCL (original magnification 200x).
Figure 3: Mediolateral oblique view of the left breast shows a rim of density surrounding the silicone implant (white arrow).







IA). The optimal treatment for patients with this stage is
a complete surgical excision of the prosthesis and the cap-
sule [10–13]. Consequently, our patient underwent bilateral
capsulectomy and the right and left periprosthetic capsules
were analyzed. Both capsules were entirely sampled and one
section of each block was analyzed with particular attention
to the luminal side. The histological and immunohistochem-
ical analysis of the periprosthetic capsule did not show
lymphomatous infiltration. A CD30 immunohistochemistry
performed on each slide was negative. Three weeks after
the surgery, the patient underwent a PET/CT scan which
showed a discrete parieto-thoracic bilateral hyperfixation
with a slightly more intense signal at the level of the 3rd right
chondrocostal junction. However, this signal is unspecific
given the postsurgical context. The disease was localized
and no standard approach for systemic treatment for this
patient was recommended [12]. Now, the patient has been
disease-free with no evidence of disease recurrence for two
years.
2.2. Case 2. A 47-year-old woman came to our center with an
increase in volume of her left breast without sign of infection.
She is the mother of two children, without hormonal treat-
ment. She has no hereditary history of breast cancer. In 2004,
a breast augmentation was performed using retropectoral
textured silicone gel implants, Allergan style 110, 330cc. The
clinical examination revealed that her breasts were slightly
dissymmetrical. The left breast was much larger than the
right without suspicious mass detected and no palpable
lymphadenopathy. On the mammography, the mediolateral
oblique (MLO) view without compression demonstrates that
the left prosthesis is deformed on its anterior pole and a
periprosthetic collection developed mainly on the anterior
surface of the prosthesis (Figure 3). In Eklund incidence, no
lesion is observed. We then performed a bilateral ultrasound.
This exam did not show any tumoral lesion or cyst in both
breasts. But it confirmed the existence of a significant left
periprosthetic fluid reaction predominant in the inner region
(Figure 4). To get a diagnosis, a partial evacuation by fine
needle aspiration is performed. The bacteriologic analysis of
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Figure 4: Ultrasound of the left breast demonstrates periprosthetic fluid reaction in the inner region (white arrow).
(a) (b)
Figure 5: Case 2, (a) H&E section of the cell block preparation from effusion fluid showing atypical lymphocytes; (b) CD30
immunohistochemistry highlights tumor cells positive for CD30 (original magnification 200x).
a part of this sample demonstrated no infectious sign. The
pathologic evaluation of the second part of this sample identi-
fied atypical cells (Figure 5(a)) and a positivity for CD30 (Fig-
ure 5(b)). Immunohistochemical analysis demonstrated an
expression of CD45 and CD3. The cells did not express ALK
and CK7. This sample was also submitted for a blind analysis
to four independent anatomopathologists who all came to
the conclusion of a breast implant-associated anaplastic
large cell lymphoma. For this patient, the BIA-ALCL-specific






(Stage IA). The patient
underwent bilateral implant removal and capsulectomy. The
total samples were analyzed. Similarly to the first case, no
lymphomatous infiltration was found in the periprosthetic
capsule and CD30 remained negative on each slides. Fifteen
days after the surgery the patient received a PET/CT scan
which showed a slight hypermetabolic area in the left side but
unspecific.No othermetabolic lesionwas found. Considering
the stage of the disease and the complete surgical excision
including total capsulectomy and the absence of lymphoma-
tous infiltration, no additional treatment was performed.The
patient remains clinically well after 24 months of followup
under close surveillance by our center and hematology
clinic.
3. Discussion
In this study, we described two case reports of BIA-ALCL,
consisting of an anaplastic proliferation with “hallmark” cells
confined to the capsule associated with a seroma. Contrary
to the other studies, the diagnosis was confirmed before
performing the capsulectomy. Indeed, the mammographies
without compression showed clearly a periprosthetic effu-
sion. Moreover, ultrasound imaging is one of the most
sensitive techniques for the detection of peri-implant fluid
collection and has the added benefit of being readily available
for ultrasound image guided aspiration and diagnosis [15,
16]. The histological and immunohistochemical analyses and
consequently the diagnosis of BIA-ALCL were established
from the fine needle aspiration performed by the senologist.
The first treatment for BIA-ALCL is the removal of the
implant and the resection of the entire capsule [12, 17–19].
In the cases presented here, the anatomopathological analysis
of the periprosthetic capsule, following the capsulectomy,
demonstrated the absence of lymphomatous infiltration. But
that does not call into doubt the diagnostic of BIA-ALCL
proven with the needle aspiration. The drainage of the effu-
sion may indeed lead to reaccumulation of the fluid in a few
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weeks but the number of lymphoma cellsmay be considerably
decreased by dilution and neutrophils or histiocytes are
generally observed [13]. Laurent et al. demonstrated in a
retrospective study that complete capsulectomy and implant
removal is required for all cases of BIA-ALCL and adjuvant
therapy is considered according to the subtype [9]. An
incomplete resection or positivemargins or advanced disease
require chemotherapy and chest wall radiation. Anti-CD30
immunotherapy and stem cell transplant are actually under
investigation [17].
Previous studies reported different incidences of devel-
oping ALCL in women with breast implants [19, 20] and
the most recent report by Clemens M. in FDA estimated
the risk between 1 per 3817 to 1 per 30 000 women with
textured implant [8]. Thus, it seems important to report
in the literature every case of BIA-ALCL and determine if
similarities are observed between the different cases. The
published data have already produced interesting findings.
One of the common factors for the cases reported in the
literature is the type of implant. In our two cases, the implant
surface is textured. Many studies have already reported a
possible link between the implant surface and the BIA-
ALCL pathology. Indeed, it is possible that, with a textured
surface in particular, an immunologic response could develop
due to chronic irritation by the prosthesis [9, 21]. Some
authors have suggested that the trigger for local inflammatory
response lies in the presence of silicone-derived products or
specific bacterial species adherent to the prosthesis surface
(biofilm) [20, 22]. The median interval time between breast
implant surgery and BIA-ALCL diagnosis is 9 years [13].
Thus, the implant must be in place for a long time before
the pathology appears. This adds an additional explanation
to the development of BIA-ALCL. The irritation caused by
the textured implant occurs long after the surgery and the
development of the pathology. Some cases of BIA-ALCL
with smooth-implant have been reported, but no details
concerning previous surgery with breast implant silicone
have been listed. The FDA confirmed that BIA-ALCL is
predominantly associated with textured surface implants [8].
Therefore, a systematic description of each implant,
ideally the reference/manufacturer, and a list of all surgeries
made on the patient must be reported for new cases. A lot of
studies report BIA-ALCLwithout disruption of the prosthesis
like our two cases, suggesting that there is no influence on the
development of this pathology [9].
Moreover, the increasing number of breast prosthesis
implanted could result in an increased of diagnoses of breast
implant-associated ALCL thus encouraging clinical and
radiological surveillance of these patients. Radiologists and
senologists must be particularly attentive when they observe
a rapid increase in breast volume of patients with breast
prosthesis. In November 2018, the superior health council of
Belgium also provided recommendations for the detection,
registration, and follow-up of BIA-ALCL. In their report, they
recommend plastic surgeons include an informed consent
about the risk of developing BIA-ALCL for patients having an
augmentation or breast reconstruction using implants [23].
In conclusion, our study reinforce the need to report each
case of BIA-ALCL to better understand this rare pathology
and demonstrates the use of a new approach to highlight
periprosthetic effusion or modification of the prosthesis.
Mammography without compression allows us to correctly
locate the prosthesis (retropectoral or retroglandular) and
search for disruption of the prosthesis or liquid collection.
When BIA-ALCL is suspected on mammography, it is also
recommended to perform an echography and a fine needle
aspiration of seroma followed by cytological evaluation and
CD30 immunohistochemistry.
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This figure demonstrates a CD30 stain performed on the
capsules for each case. CD30 immunohistochemistry remains
negative. (a) Case 1; (b) Case 2. (Supplementary Materials)
References
[1] S. S. Talwalkar, R. N. Miranda, J. R. Valbuena, M. J. Routbort,
A. W. Martin, and L. J. Medeiros, “Lymphomas involving the
breast: a study of 106 cases comparing localized and dissemi-
nated neoplasms,” The American Journal of Surgical Pathology,
vol. 32, no. 9, pp. 1299–1309, 2008.
[2] R. Giardini, C. Piccolo, and F. Rilke, “Primary Non-Hodgkin’s
lymphomas of the female breast,”Cancer, vol. 69, no. 3, pp. 725–
735, 1992.
[3] P. Validire, M. Capovilla, B. Asselain et al., “Primary breast non-
Hodgkin’s lymphoma: a large single center study of initial char-
acteristics, natural history, and prognostic factors,” American
Journal of Hematology, vol. 84, no. 3, pp. 133–139, 2009.
[4] G. Gualco, L. Chioato, W. J. Harrington Jr., L. M. Weiss,
and C. E. Bacchi, “Primary and secondary T-cell lymphomas
of the breast: clinico-pathologic features of 11 cases,” Applied
Immunohistochemistry & Molecular Morphology , vol. 17, no. 4,
pp. 301–306, 2009.
[5] D. Lazzeri, T. Agostini, G. Bocci et al., “ALK-1–Negative
Anaplastic Large Cell Lymphoma Associated With Breast
Implants: A New Clinical Entity,” Clinical Breast Cancer, vol. 11,
no. 5, pp. 283–296, 2011.
[6] J. A. Keech Jr. and B. J. Creech, “Anaplastic T-cell lymphoma
in proximity to a saline-filled breast implant,” Plastic and
Reconstructive Surgery, vol. 100, no. 2, pp. 554-555, 1997.
[7] A. L. Feldman, N. L. Harris, and H. Stein, “Breast implant-
associated anaplastic large cell lymphoma,” in WHO classifi-
cation of tumours of haematopoietic and lymphoid tissues, S.
H. Swerdlow, E. Campo, N. L. Harris et al., Eds., IARC, Lyon,
France, 4th edition, 2017.
[8] M. W. Clemens, “BIA-ALCL Ressources. By the numbers, and
what they meen. ASPS Spring meeting,” 2019, https://www
.plasticsurgery.org/for-medical-professionals/health-policy/
bia-alcl-physician-resources/by-the-numbers.
[9] C. Laurent, A. Delas, P. Gaulard et al., “Breast implant- associ-
ated anaplastic large cell lymphoma: two distinct clinicopatho-
logical variants with different outcomes,” Annals of Oncology,
vol. 27, no. 2, pp. 206–314, 2016.
6 Case Reports in Radiology
[10] D. Cezkwudo, T. Ifabiyi, B. Gbadamosi et al., “Breast implant-
associated anaplastic large cell lymphoma: a case report and
review of the literature,” Case Reports in Oncological Medicine,
pp. 1–6, 2017.
[11] M. W. Clemens, L. J. Medeiros, C. E. Butler et al., “Com-
plete surgical excision is essential for the management of
patients with breast implant–associated anaplastic large-cell
lymphoma,” Journal of Clinical Oncology, vol. 34, no. 2, pp. 160–
168, 2016.
[12] N. Mehta-Shah, M. W. Clemens, and S. M. Horwitz, “How I
treat breast implant–associated anaplastic large cell lymphoma,”
Blood, vol. 132, no. 18, pp. 1889–1898, 2018.
[13] A. E. Quesada, L. J. Medeiros, and M. W. Clemens, “Breast
implant-associated anaplastic large cell lymphoma: a review,”
Modern Pathology, vol. 32, pp. 166–188, 2019.
[14] G. Eklund, R. Busby, S. Miller, and J. Job, “Improved imaging of
the augmented breast,” American Journal of Roentgenology, vol.
151, no. 3, pp. 469–473, 1988.
[15] H. Letter, B. Rop, M. N. Edison, and P. Turner, “Breast implant-
associated anaplastic large cell lymphoma: a case report and
literature review,” Cureus, vol. 8, no. 3, 2016.
[16] A. Rupani, J. D. Frame, and D. Kamel, “Lymphomas associated
with breast implants: a reviewof the literature,”Aesthetic Surgery
Journal, vol. 35, no. 5, pp. 533–544, 2015.
[17] M. Clemens and R. Miranda, “Coming of age breast implant-
associated anplastic large cell lymphoma after 18 years of
investigation,” Clinics in Plastic Surgery, pp. 1–8, 2015.
[18] M. W. Clemens, L. J. Medeiros, C. E. Butler et al., “Surgical
excision is essential for the management of patients with breast
implant-associated anaplastic large-cell lymphoma,” Journal of
Clinical Oncology, vol. 10, pp. 160–168, 2016.
[19] M.W. Clemens, G. S. Brody, R. C. Mahabir, and R. N. Miranda,
“How to diagnose and treat breast implant–associated anaplas-
tic large cell lymphoma,” Plastic and Reconstructive Surgery, vol.
141, no. 4, pp. 586e–599e, 2018.
[20] M. de Boer, F. E. van Leeuwen, M. Hauptmann et al., “Breast
implants and the risk of anaplastic large-cell lymphoma in the
breast,” JAMA Oncology, vol. 4, no. 3, p. 335, 2018.
[21] G. S. Brody, D. Deapen, C. R. Taylor et al., “Anaplastic large cell
lymphoma occurring in women with breast implants,” Plastic
and Reconstructive Surgery, vol. 135, no. 3, pp. 695–705, 2015.
[22] H. Hu, K. Johani, A. Almatroudi et al., “Bacterial biofilm infec-
tion detected in breast implant–associated anaplastic large-cell
lymphoma,” Plastic and Reconstructive Surgery, vol. 137, no. 6,
pp. 1659–1669, 2016.
[23] Federal Public Service Health and Food Chain Safety And


















































































Submit your manuscripts at
www.hindawi.com
